ClearOne Inc. stocks have been trading up by 52.43 percent amid strong investor optimism driven by recent positive developments.
Click Here for a Millionaire's POV on Trading CLRO
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- ClearOne is merging with Cortigent, a Vivani Medical neurostimulation spinout, and will rebrand as Cortigent Holdings, trading on Nasdaq as CRGT.
- Vivani Medical is set to own roughly 59–68% of the combined company, with legacy ClearOne holders diluted down to about 13–14%.
- The deal includes an S-1 equity raise of roughly $10–$15M at closing to fund the new BCI-focused med-tech company.
- Around 12.5M new shares will be issued to Vivani, sharply diluting existing CLRO shareholders and shifting control.
- Following the announcement, CLRO ripped higher, with reports citing a 155% surge on heavy volume and another noting a gain of more than 14%.
Live Update At 10:02:53 EDT: On Tuesday, July 07, 2026 ClearOne Inc. stock [NASDAQ: CLRO] is trending up by 52.43%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CLRO just turned into a classic trader’s rollercoaster. Before the Cortigent news hit, ClearOne was grinding around the low-$3s. The chart shows a quiet base between roughly $3.10 and $3.70 through late June, with modest swings and limited excitement.
Then the merger headlines landed. On 2026/07/02, CLRO exploded from a $3.60 open to an intraday high near $9.62, closing at $6.48. That kind of range tells traders one thing: serious volume and serious emotion. The follow‑through has been real so far. By 2026/07/06, CLRO closed at $7.00, and on 2026/07/07 it pushed to a $10.67 close after hitting $10.67 intraday.
Intraday, CLRO has been a wild scalp. On the most recent session, the stock swung from the low-$8s to over $10 in minutes. That’s the kind of volatility day traders hunt, but it also punishes anyone who chases without a plan.
Fundamentally, ClearOne’s latest quarterly numbers show a small company still losing money. CLRO reported a net loss of about $487,000 for Q1 2026, negative operating cash flow around $680,000, and total assets of just over $2.0M. The balance sheet carries roughly $875,000 in current liabilities and $1.5M in total liabilities, with a current ratio near 1.9 and cash of about $756,000.
More Breaking News
- PTGX Stock Grinds Higher As Pipeline Catalysts Build
- EOSE Stock Slides As Massive Capital Raise Funds Frontier Power Bet
- IOTR Stock Jumps As Traders Zero In On Breakout
- Alibaba Stock Jumps As Traders Weigh DOJ Hit And AI Pivot
So you have a thinly capitalized, money‑losing business whose market value is now being completely re-rated based on the Cortigent merger and the shift into neurostimulation and brain‑computer interface tech.
Why Traders Are Watching CLRO’s Cortigent Pivot
Traders are glued to CLRO right now because this isn’t just a routine deal. ClearOne is effectively handing the steering wheel to Cortigent and Vivani Medical and turning itself into a new BCI‑focused med‑tech story under the future ticker CRGT.
The core of the news: ClearOne is merging with Cortigent, Cortigent becomes a wholly owned subsidiary, and the combined company gets renamed Cortigent Holdings and uplisted to Nasdaq as CRGT. For CLRO, which has been a small-cap communications and conferencing name, that’s a total narrative reset. New sector, new peer group, new way the market might value the stock.
The market’s first reaction was pure momentum. Reports show CLRO soaring as much as 155% on extremely heavy volume after the Vivani subsidiary agreed to merge with a ClearOne unit. Another report cites a more modest 14%+ jump on the announcement. Either way, that kind of wide range in reported gains screams volatility and active price discovery. Traders are rushing in, and the tape is still figuring out what CLRO is worth in this new skin.
But buried inside the excitement is heavy dilution. CLRO will issue about 12.5M new shares to Vivani. Post‑deal, Vivani is expected to own roughly 59–68% of Cortigent Holdings, while legacy ClearOne shareholders keep only about 12.7–14.4%. That means current CLRO holders become minority partners in whatever upside this med‑tech story may deliver.
On top of that, ClearOne plans to raise about $10–$15M via an S‑1 financing at closing. Fresh capital should help fund Cortigent’s neurostimulation roadmap, yet it also sets up another source of dilution and an overhang around the offering price. For active CLRO traders, all of this combines into a high‑beta setup: big story, big volume, and big risk on every candle.
Conclusion
CLRO is no longer just a sleepy micro‑cap audio name; it’s morphing into a speculative BCI‑med‑tech vehicle tied closely to Vivani Medical’s Cortigent unit. The share‑price spike from the $3s into double digits shows how quickly sentiment can flip when a small stock announces a transformational merger and a Nasdaq rebrand.
But traders need to read the fine print. With Vivani expected to own roughly 59–68% of Cortigent Holdings and legacy ClearOne shareholders holding only about 13–14%, the slice of the future pie for current CLRO holders is much smaller than the headline pop suggests. The 12.5M new shares issued to Vivani, plus the planned $10–$15M S‑1 raise, mean significant dilution baked into the structure.
This is the kind of setup Tim Sykes and the StocksToTrade community study every day: hot news, massive volume, and a crowded momentum trade built on a complex deal. As Sykes likes to say, “The pattern repeats, but you have to manage your risk because these spikes can fade faster than you think.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. For traders, CLRO is now a pure catalyst and volatility play, not a sleepy long‑term hold. Know the story, respect the dilution, and, above all, trade the price action—not the hype.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.